U.S. Markets open in 8 hrs 15 mins
  • S&P Futures

    4,065.25
    -10.25 (-0.25%)
     
  • Dow Futures

    34,011.00
    -12.00 (-0.04%)
     
  • Nasdaq Futures

    12,041.25
    -65.50 (-0.54%)
     
  • Russell 2000 Futures

    1,906.30
    -4.20 (-0.22%)
     
  • Crude Oil

    81.42
    +0.41 (+0.51%)
     
  • Gold

    1,925.50
    -4.50 (-0.23%)
     
  • Silver

    23.93
    -0.09 (-0.37%)
     
  • EUR/USD

    1.0877
    -0.0015 (-0.1414%)
     
  • 10-Yr Bond

    3.4930
    0.0000 (0.00%)
     
  • Vix

    18.73
    -0.35 (-1.83%)
     
  • GBP/USD

    1.2381
    -0.0026 (-0.2105%)
     
  • USD/JPY

    129.8500
    -0.3030 (-0.2328%)
     
  • BTC-USD

    23,005.42
    -168.02 (-0.73%)
     
  • CMC Crypto 200

    520.82
    -6.36 (-1.21%)
     
  • FTSE 100

    7,761.11
    +16.24 (+0.21%)
     
  • Nikkei 225

    27,388.14
    +25.39 (+0.09%)
     

Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference

Wave Life Sciences USA, Inc.
Wave Life Sciences USA, Inc.

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on Wednesday, November 16, 2022, at 3:35 p.m. ET.

A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. Replays of this presentation will be archived and available on the site for a limited time following the event.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.


Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com